Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Akhila Balasubramanian"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionThe treatment landscape of small cell lung cancer (SCLC) is evolving. Evidence generated from administrative claims is needed to characterize real-world SCLC patients. However, the current ICD-10 coding system cannot distinguish SCLC from
Externí odkaz:
https://doaj.org/article/0ee4a5300bcf4613b5d48073afe4ded0
Autor:
Min Kim, Tzu‐Chieh Lin, Tarun Arora, Hong Zhao, Akhila Balasubramanian, Robert Kees Stad, James O'Kelly, Leslie Spangler, Brian D. Bradbury, Jeffrey R. Curtis
Publikováno v:
Journal of Bone and Mineral Research.
Autor:
Mark D. Danese, Jennifer Schenfeld, Jaime Shaw, Prasad Gawade, Akhila Balasubramanian, Michael Kelsh, Rohini K. Hernandez, Gary Lyman
Publikováno v:
Advances in Therapy. 39:2778-2795
Patients diagnosed with cancer have an increased risk both for myelodysplastic syndromes (MDS) and for acute myeloid leukemia (AML) following treatment.Using SEER-Medicare data, we selected patients aged 66 years and older who completed systemic ther
Autor:
Akhila Balasubramanian, Mary Elkins Melton, Jeffrey R. Curtis, Shanette G. Daigle, Nicole C. Wright, Elizabeth Delzell
Publikováno v:
Journal of Bone and Mineral Research. 34:1798-1807
Our study validated a claims-based algorithm for the identification of incident and recurrent fractures in administrative data. We used Centers for Medicare and Medicaid (CMS) claims from 2005 to 2014 linked to the Reasons for Geographic and Racial D
Autor:
Michael Ittmann, Stacy M. Lloyd, Danthasinghe Waduge Badrajee Piyarathna, Arun Sreekumar, Akhila Balasubramanian, Patricia Castro, James M. Arnold, Nora M. Navone, Wendong Yu, Vlad C. Sandulache, Nagireddy Putluri, Balasubramanyam Karanam, George Michailidis, Andrew G. Sikora, Jeffrey A. Jones
Publikováno v:
Journal of Clinical Investigation. 129:2351-2356
Background African American (AA) patients have higher cancer mortality rates and shorter survival times compared to European American (EA) patients. Despite a significant focus on socioeconomic factors, recent findings strongly argue the existence of
Autor:
Shanette G. Daigle, Akhila Balasubramanian, Jeffrey R. Curtis, Jie Zhang, Andreas Grauer, Deborah Wenkert, Lang Chen
Publikováno v:
Osteoporosis International
Summary Among 377,561 female Medicare beneficiaries who sustained a fracture, 10% had another fracture within 1 year, 18% within 2 years, and 31% within 5 years. Timely management to reduce risk of subsequent fracture is warranted following all nontr
Autor:
Robert A. Adler, Jeffrey R. Curtis, Akhila Balasubramanian, Nicola Pannacciulli, Kenneth G. Saag, Sally W. Wade
Publikováno v:
Journal of Bone and Mineral Research. 33:1881-1888
The purpose of this work was to evaluate systemic glucocorticoid exposure and fracture among patients with newly-diagnosed inflammatory and immune-modulated conditions. Using administrative data, inception cohorts of rheumatoid arthritis (RA), asthma
Autor:
Darcie Sandschafer, Jennifer Schenfeld, Reshma Mahtani, Akhila Balasubramanian, Jaime Shaw, Michael A. Kelsh, Renee R Jaramillo
Publikováno v:
Journal of Clinical Oncology. 39:314-314
314 Background: FN is a primary driver of chemotherapy modification and reduced RDI. Breast cancer patients often receive regimens with high risk ( > 20%) for FN. PP G-CSF use is recommended to decrease incidence of infection, as manifested by FN. Re
Autor:
Onchee Yu, Denise M. Boudreau, Andreas Grauer, Delia Scholes, Daria B. Crittenden, Heidi S. Wirtz, Akhila Balasubramanian
Publikováno v:
Journal of the American Geriatrics Society. 65:1829-1835
Objectives To identify women's beliefs and other factors associated with lack of osteoporosis (OP) pharmacotherapy (OP-RX) during the 6 months after a fragility fracture, including the woman's perspective on fracture risk, OP, and treatment. Design C
Autor:
Franklin Gu, Nagireddy Putluri, Weijie Zhang, Arun Sreekumar, Akhila Balasubramanian, Aryan M.A. Namboodiri, Stefan Ambs, Xiang Zhang, Chandra Ambati
Publikováno v:
Cancer Research. 80:PO-056
Breast cancer (BCa) is a disease that affects over a quarter million women in the US every year. Our laboratory studies reprogrammed energy metabolism in BCa, which is an essential hallmark of the disease. Specifically, we focus on the metabolic rewi